期刊文献+

应用液体蛋白芯片飞行时间质谱系统研究卵巢癌的血清蛋白表达谱 被引量:6

Proteomic profiling of ovarian cancer in serum using magnetic bead based sample fractionation and MALDI-TOF MS
下载PDF
导出
摘要 目的:应用液体蛋白芯片飞行时间质谱系统分析卵巢癌的血清蛋白质表达谱,寻找具有潜在诊断意义的血清标志物,以利于卵巢癌的早期诊断。方法:收集2组卵巢肿瘤患者(其中卵巢浆液性乳头状囊腺癌20例、卵巢浆液性乳头状囊腺瘤9例)和1组正常人(10例)血清样本,经ClinProt磁珠纯化、基质辅助激光解析电离飞行时间质谱(MALDI-TOF-MS)分析及ClinProTools生物信息学方法研究其血清蛋白表达谱。每组样品重复检测3次。结果:3组血清样品的蛋白丰度的平均变异系数(CV值),分别为0.151、0.246和0.147,证实该试验标准具有良好重复性。质荷比(m/z)为1451和2673的蛋白峰能较好地鉴别卵巢癌和非癌组。结论:液体蛋白芯片飞行时间质谱系统作为研究蛋白表达谱的工具,具有较好的重复性与精度,筛选得到的m/z为1451和2673的蛋白可能为潜在的卵巢癌肿瘤标志物。 Objective:To establish proteomic profiling using functional magnetic bead based sample fractionation method combinded with matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) technology and to seek potential biomarkers of ovarian cancer for early diagnosis. Methods: The plasma protein profiling of two groups of patients with ovarian tumors (including 20 ovarian papillary cystadenocarcinoma patients and 9 ovarian papillary cystadenoma patients) and one group of 10 normal controls by the ClinProt magnetic bead enrichment and MALDI-TOF-MS was analyzed. Every group was repeated 3 times. Results:The mean coefficients of variance (CV) for protein peak intensities in three groups were 0. 151,0. 246 and 0. 147, respectively which were small. Two peaks with mass charge ratio (m/z) 1451 and 2673 optimally discriminated ovarian cancer from non-cancer control group. Condusions:Functional magnetic bead based sample fractionation method combined with MALDI-TOF-MS is accurate and stable. Protein peaks with m/z 1451 and 2673 may be potential biomarkers for ovarian cancer.
出处 《现代妇产科进展》 CSCD 北大核心 2008年第2期88-91,共4页 Progress in Obstetrics and Gynecology
基金 国家自然科学基金资助项目(No:39970763、30471807)
关键词 卵巢肿瘤 液体蛋白芯片飞行质谱 蛋白质谱 早期诊断 Ovarian neoplasms ClinProt system Proteomic profiling Early diagnosis
  • 相关文献

参考文献11

  • 1Jemal A, Thomas A, Murray T, et al. Cancer Statistics [J]. CA Cancer J Clin,2002,52:23-47.
  • 2Cheng A J, Chen LC, Chien KY, et al. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology [ J ]. Clin Chem, 2005,51 : 2236- 2244.
  • 3Zhang X,Leung SM,Morris CR,et al. Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma [ J ]. J Biomol Tech,2004,15 : 167-175.
  • 4Villanueva J, Philip J, Entenberg D, et al. Serum peptide profiling by magnetic particle assisted,automated sample processing and MALDI-TOF mass spectrometry [ J ]. Anal Chem,2004,76 : 1560-1570.
  • 5Zhang H, Kong B, Qu X, et ai. Biomarker discovery for ovarian cancer using SELDI-TOF-MS [ J ]. Gynecol Oncol, 2006,102:61-66.
  • 6Conrads TP, Fusaro VA, Ross S,et al. High-resolution serum proteomic features for ovarian cancer detection [ J ]. Endocr Relat Cancer,2004,11 : 163-178.
  • 7Kozak KR, Antaeus MW, Pusey SM, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange protein chips:potential use in diagnosis and prognosis [ J]. PNAS,2003,100 : 12343-12348.
  • 8Rai A J, Zhang Z, Rosenzweig J, et al. Proteomic approaches to tumor marker discovery [ J ]. Arch Pathol Lab Med ,2002,126:1518-1526.
  • 9Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer [ J ]. Lancet, 2002,359 : 572 -577.
  • 10Schuerenberg M,Luebbert C ,Eickhoff H,et al. Prestructured MALDI-MS sample supports [ J ]. Anal Chem, 2000,72:3436-3442.

同被引文献45

引证文献6

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部